We examined intraepithelial lymphocytes (IELs) in 213 ileal biopsies from 16 bowel grafts and compared them with 32 biopsies from native intestines. During the first year posttransplantation, grafts exhibited low levels of IELs (percentage of CD103 cells) principally due to reduced CD3CD8 cells, while CD103CD3 cell numbers became significantly higher. Changes in IEL subsets did not correlate with histology results, isolated intestine, or multivisceral transplants, but CD3 IELs were significantly higher in patients receiving corticosteroids. Compared with controls, more CD3 IELs of the grafts expressed CD56, NKp44, interleukin (IL)-23 receptor, retinoid-related orphan receptor gamma t (RORγt), and CCR6. No difference was observed in granzyme B, and CD3CD127 cells were more abundant in native intestines. Ex vivo, and after in vitro activation, CD3 IELs in grafts produced significantly more interferon (IFN)-γ and IL-22, and a double IFNγIL-22 population was observed. Epithelial cell–depleted grafts IELs were cytotoxic, whereas this was not observed in controls. In conclusion, different from native intestines, a CD3 IEL subset predominates in grafts, showing features of natural killer cells and intraepithelial ILC1 (CD56, NKp44, CCR6, CD127, cytotoxicity, and IFNγ secretion), ILC3 (CD56, NKp44, IL-23R, CCR6, RORγt, and IL-22 secretion), and intermediate ILC1–ILC3 phenotypes (IFNγIL-22). Viability of intestinal grafts may depend on the balance among proinflammatory and homeostatic roles of ILC subsets.